Trials / Unknown
UnknownNCT05363800
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 198 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and refractory Non-Hodgkin's lymphoma and multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-3738 | HRS-3738 will be administrated per dose level in which the patients are assigned. |
Timeline
- Start date
- 2022-06-17
- Primary completion
- 2024-10-30
- Completion
- 2024-12-30
- First posted
- 2022-05-06
- Last updated
- 2022-07-29
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05363800. Inclusion in this directory is not an endorsement.